CAGR Of 4.8%: Global Alopecia Drugs Market about to hit CAGR of 4.8% from 2017 to 2026

The global alopecia drugs market was valued at US$ 6,901.8 Mn in 2016 and is projected to reach US$ 10,992.9 Mn in 2026 at a CAGR of 4.8% from 2017 to 2026. The topical segment in the global alopecia drugs market accounted for a major revenue share of 69.8% owing to factors such as easy absorption of medications by hair follicles, along with easier administration and application as compared to other forms.

Global Alopecia Drugs Market: Segmental Snapshot

By route of administration: The topical segment is estimated to register a CAGR of over 5.1%, thereby accounting for highest revenue share among the route of administration segments.

By gender: The men segment is estimated to account for highest revenue share among the gender segments, registering a CAGR of over 5.0% during the forecast period.

By region: The market in Asia Pacific is expected to record highest CAGR of over 7.3% between 2017 and 2026.

Global Alopecia Drugs Market: Competitive Analysis

The research report on the global alopecia drugs market includes detailed competitive analysis on major companies such as Taisho Pharmaceutical Holdings Co. Ltd., The Himalaya Drug Company, Johnson & Johnson Services, Inc., GlaxoSmithKline Plc., Cipla Inc., Dr. Reddy’s Laboratories Ltd., MERCK, Vitabiotic Ltd., and Sun Pharmaceutical Industries Ltd.

Infographic by Global alopecia drugs market

This entry was posted in Health.